X0306 4 2018-11-21 0 0001217234 CareDx, Inc. CDNA 0001613855 Maag Peter C/O CAREDX, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005 1 1 0 0 See Remarks Common Stock 2018-11-21 4 M 0 50000 0.548 A 439747 D Common Stock 2018-11-21 4 M 0 37636 6.49 A 477383 D Common Stock 2018-11-21 4 M 0 23158 5.49 A 500541 D Common Stock 1000 I As UTMA custodian for minor child Common Stock 1000 I As UTMA custodian for minor child Stock Option (Right to Buy) 0.548 2018-11-21 4 M 0 50000 0.00 D 2012-11-01 2022-10-17 Common Stock 50000 0 D Stock Option (Right to Buy) 6.49 2018-11-21 4 M 0 37636 0.00 D 2025-03-06 Common Stock 37636 42364 D Stock Option (Right to Buy) 5.49 2018-11-21 4 M 0 23158 0.00 D 2024-11-09 Common Stock 23158 46316 D Shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. 2/48ths of the shares subject to this option vested and became exercisable on the Date Exercisable set forth in column 6 and each month thereafter until October 1, 2013. 1/36th of the remaining shares vested and became exercisable each month thereafter. 1/4th of the shares subject to this option vested on January 21, 2016 and 1/48th of the shares subject to this option vest monthly thereafter. The shares subject to this option vest in three equal installments based upon the Issuer's achievement of certain performance goals as follows: (i) one third of the shares subject to the option vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after November 8, 2017, (ii) one third of the shares subject to the option vest upon the Issuer's determination, which has been reviewed by the Issuer's independent registered public accounting firm, that the Issuer has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after November 8, 2017 (Continued from Footnote 4) and (iii) one third of the shares subject to the option vested upon the closing sales price of the Issuer's common stock being at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after November 8, 2017. President and Chief Executive Officer /s/ Peter Maag 2018-11-21